TrialNCT07405151
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Status
- RECRUITING
- Phase
- PHASE1, PHASE2
- Last update posted
- 09/03/2026
- Start
- 03/27/2026
- Sponsor
- Merck Sharp & Dohme LLC
- Specialties
- otolaryngology, oncology
Conditions: Oesophageal Squamous Cell Carcinoma
Brief summary
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.